Stephens Reaffirms "Equal Weight" Rating for Evolent Health (NYSE:EVH)

Key Points

• Stephens has reaffirmed an "equal weight" rating for Evolent Health (NYSE:EVH) with a price target of $9.00, suggesting a potential upside of 7.08% from the stock’s previous close.
• Several brokerages have rated Evolent Health positively, with Truist Financial increasing their price target to $16.00 and BTIG Research to $20.00, indicating a general consensus of a "buy" rating among analysts.
• Evolent Health recently reported a loss of $0.10 earnings per share for the last quarter, missing analyst expectations, and its revenue decreased by 31.3% compared to the same quarter last year.

Evolent Health (NYSE:EVH - Get Free Report)'s stock had its "equal weight" rating reaffirmed by equities research analysts at Stephens in a research report issued to clients and investors on Wednesday,Benzinga reports. They presently have a $9.00 price objective on the technology company's stock. Stephens' target price would indicate a potential upside of 7.08% from the stock's previous close.

Several other brokerages also recently weighed in on EVH. Truist Financial upped their price target on Evolent Health from $14.00 to $16.00 and gave the stock a "buy" rating in a report on Thursday, July 17th. BTIG Research reiterated a "buy" rating and issued a $20.00 price objective on shares of Evolent Health in a report on Tuesday, September 9th. Canaccord Genuity Group reiterated a "buy" rating and issued a $16.00 price objective on shares of Evolent Health in a report on Tuesday, September 9th. JMP Securities reiterated a "market outperform" rating and issued a $13.00 price objective on shares of Evolent Health in a report on Friday, June 20th. Finally, Piper Sandler raised their price target on Evolent Health from $16.00 to $18.00 and gave the stock an "overweight" rating in a research note on Thursday, August 28th. One equities research analyst has rated the stock with a Strong Buy rating, twelve have assigned a Buy rating and one has given a Hold rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of "Buy" and an average target price of $17.21.

Evolent Health Price Performance

EVH opened at $8.41 on Wednesday. The stock's 50-day moving average price is $9.42 and its 200 day moving average price is $9.48. Evolent Health has a 12-month low of $7.06 and a 12-month high of $30.33. The company has a current ratio of 1.01, a quick ratio of 1.01 and a debt-to-equity ratio of 0.72. The firm has a market cap of $987.66 million, a price-to-earnings ratio of -5.22 and a beta of 0.73.

Evolent Health (NYSE:EVH - Get Free Report) last issued its quarterly earnings results on Thursday, August 7th. The technology company reported ($0.10) earnings per share for the quarter, missing the consensus estimate of $0.10 by ($0.20). Evolent Health had a positive return on equity of 1.83% and a negative net margin of 5.94%.The company had revenue of $444.33 million for the quarter, compared to analysts' expectations of $459.43 million. During the same quarter last year, the company earned $0.30 EPS. Evolent Health's revenue for the quarter was down 31.3% compared to the same quarter last year. Evolent Health has set its Q3 2025 guidance at EPS. As a group, sell-side analysts expect that Evolent Health will post 0.08 earnings per share for the current year.

Institutional Trading of Evolent Health

Several hedge funds have recently modified their holdings of the business. Osaic Holdings Inc. lifted its holdings in shares of Evolent Health by 99.2% in the 2nd quarter. Osaic Holdings Inc. now owns 11,119 shares of the technology company's stock valued at $125,000 after buying an additional 5,537 shares during the period. State of Wyoming boosted its position in Evolent Health by 38.6% during the second quarter. State of Wyoming now owns 45,999 shares of the technology company's stock worth $518,000 after purchasing an additional 12,812 shares in the last quarter. Hudson Bay Capital Management LP boosted its position in Evolent Health by 92.2% during the second quarter. Hudson Bay Capital Management LP now owns 760,211 shares of the technology company's stock worth $8,560,000 after purchasing an additional 364,664 shares in the last quarter. Headlands Technologies LLC purchased a new stake in Evolent Health during the second quarter worth $58,000. Finally, Tower Research Capital LLC TRC boosted its position in Evolent Health by 313.8% during the second quarter. Tower Research Capital LLC TRC now owns 14,202 shares of the technology company's stock worth $160,000 after purchasing an additional 10,770 shares in the last quarter.

About Evolent Health

Evolent Health, Inc, through its subsidiary, Evolent Health LLC, offers specialty care management services in oncology, cardiology, and musculoskeletal markets in the United States. The company provides platform for health plan administration and value-based business infrastructure. It offers administrative services, such as health plan services, pharmacy benefits management, risk management, analytics and reporting, and leadership and management; and Identifi, a proprietary technology system that aggregates and analyzes data, manages care workflows, and engages patients.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.